Burlington, Massachusetts, February 20, 2018 — MilliporeSigma, a leader in genome editing, today announced that the Korean Intellectual Property Office and the Israel Patent Office have each issued notices granting MilliporeSigma’s patent applications for the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells.
"These decisions mark the fifth and sixth patent allowances for our unique CRISPR technology to find new treatments for some of the toughest medical conditions faced today, including cancer, hereditary and rare diseases,” said Udit Batra, CEO, MilliporeSigma. “These foundational integration patents recognize our significant contributions to the genome-editing field and reinforce our commitment to evolving CRISPR technology globally.”
MilliporeSigma also has patent filings for its insertion CRISPR method in the U.S., Brazil, China, India and Japan. In December 2017, the Intellectual Property Office of Singapore awarded MilliporeSigma a patent for this technology. Earlier, in June 2017, MilliporeSigma was awarded a similar patent by the Australian patent office. The company has also received related patent awards by the European and Canadian patent offices.
MilliporeSigma is licensing these patents for applications including basic science research, agricultural biotech and therapeutic use.
MilliporeSigma recognizes the potential benefits of conducting properly defined research with genome editing because of the breakthrough therapeutic potential. Therefore, MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma’s parent company, Merck KGaA, Darmstadt, Germany has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing.
These forthcoming, fundamental patents in South Korea and Israel cover chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence — a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.
CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for a variety of medical conditions. CRISPR applications are far-ranging — from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.
With a 12-year history in the genome-editing field, MilliporeSigma was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 21,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 56,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.